Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 25;27(5):1555.
doi: 10.3390/molecules27051555.

A Multi-Technique Investigation of the Complex Formation Equilibria between Bis-Deferiprone Derivatives and Oxidovanadium (IV)

Affiliations

A Multi-Technique Investigation of the Complex Formation Equilibria between Bis-Deferiprone Derivatives and Oxidovanadium (IV)

Rosita Cappai et al. Molecules. .

Abstract

The increasing biomedical interest in high-stability oxidovanadium(IV) complexes with hydroxypyridinone ligands leads us to investigate the complex formation equilibria of VIVO2+ ion with a tetradentate ligand, named KC21, which contains two 3-hydroxy-1,2-dimethylpyridin-4(1H)-one (deferiprone) moieties, and with the simple bidentate ligand that constitutes the basic unit of KC21, for comparison, named L5. These equilibrium studies were conducted with joined potentiometric-spectrophotometric titrations, and the results were substantiated with EPR measurements at variable pH values. This multi-technique study gave evidence of the formation of an extremely stable 1:1 complex between KC21 and oxidovanadium(IV) at a physiological pH, which could find promising pharmacological applications.

Keywords: EPR spectroscopy; UV spectrophotometry; deferiprone; oxidovanadium (IV); potentiometry.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures of the ligands KC21, L5 and DFP.
Figure 2
Figure 2
Speciation plot of L5 ligand calculated with HySS [22] according to the protonation constants in Table 1.
Figure 3
Figure 3
Calculated molar absorptivity spectra of the differently protonated forms of L5 (A) and KC21 (B) ligands.
Figure 4
Figure 4
Speciation plots of VIVO2+-ligand systems calculated with HySS program [22]. Top: UV–spectrophotometric titration conditions, 1:2 VIVO2+:ligand molar ratio and ligand concentration 3 × 10−4 M and 5 × 10−4 M, respectively, for L5 and KC21, (A) L5, (B) KC21. Bottom: EPR measurements conditions, 1:2 and 1:1 VIVO2+:ligand molar ratio, respectively, for L5 and KC21 at VIVO2+ concentration 2 × 10−3 M, (C) L5, (D) KC21. Charges are omitted for simplicity.
Figure 5
Figure 5
Calculated molar absorptivity spectra of differently protonated forms of VIVO2+ complexes with L5 (A) and KC21 (B) ligands.
Figure 6
Figure 6
High field region of the anisotropic X-band EPR spectra, at increasing pH, of VIVO2+-L5 system at 1:2 VIVO2+:ligand molar ratio (A) and VIVO2+-KC21 system at 1:1 VIVO2+:ligand molar ratio (B). VIVO2+ concentration is 2 × 10−3 M.
Figure 7
Figure 7
Molecular drawings of the VIVO2+ species with the ligand KC21 based on the solution studies.

Similar articles

References

    1. Costa Pessoa J., Etcheverry S., Gambino D. Vanadium compounds in medicine. Coord. Chem. Rev. 2015;301–302:24–48. doi: 10.1016/j.ccr.2014.12.002. - DOI - PMC - PubMed
    1. Rehder D. Perspectives for vanadium in health issues. Future Med. Chem. 2016;8:325–338. doi: 10.4155/fmc.15.187. - DOI - PubMed
    1. Crans D.C., Yang L., Haase A., Yang X. Health Benefits of Vanadium and Its Potential as an Anticancer Agent. In: Sigel A., Sigel H., Freisinger E., Sigel R.K.O., editors. Metallo-Drugs: Development and Action of Anticancer Agents. De Gruyter GmbH; Berlin, Germany: 2018. pp. 251–280.
    1. Treviño S., Díaz A., Sánchez-Lara E., Sanchez-Gaytan B.L., Perez-Aguilar J.M., González-Vergara E. Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus. Biol. Trace Element Res. 2019;188:68–98. doi: 10.1007/s12011-018-1540-6. - DOI - PMC - PubMed
    1. Crans D.C., Henry L., Cardiff G., Posner B.I. Developing Vanadium as an Antidiabetic or Anticancer Drug: A Clinical and Historical Perspective. In: Carver P.L., editor. Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic. 1st ed. De Gruyter; Berlin, Germany: Boston, MA, USA: 2019. pp. 203–230. - PubMed

LinkOut - more resources